Rosetta Genomics (NASDAQ: ROSG) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Rosetta Genomics to similar businesses based on the strength of its risk, valuation, institutional ownership, profitability, earnings, dividends and analyst recommendations.
Insider & Institutional Ownership
8.3% of Rosetta Genomics shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Rosetta Genomics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Rosetta Genomics||$9.23 million||-$16.23 million||-0.06|
|Rosetta Genomics Competitors||$217.30 million||-$39.39 million||-71.36|
Rosetta Genomics’ peers have higher revenue, but lower earnings than Rosetta Genomics. Rosetta Genomics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent ratings and recommmendations for Rosetta Genomics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rosetta Genomics Competitors||528||2440||6558||124||2.65|
Rosetta Genomics currently has a consensus target price of $3.50, suggesting a potential upside of 407.25%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.26%. Given Rosetta Genomics’ stronger consensus rating and higher possible upside, research analysts plainly believe Rosetta Genomics is more favorable than its peers.
This table compares Rosetta Genomics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rosetta Genomics Competitors||-3,073.42%||-537.64%||-38.11%|
Risk & Volatility
Rosetta Genomics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Rosetta Genomics’ peers have a beta of 1.57, indicating that their average stock price is 57% more volatile than the S&P 500.
Rosetta Genomics beats its peers on 7 of the 12 factors compared.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Receive News & Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.